Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
250 participants
INTERVENTIONAL
2019-02-01
2023-07-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV)
NCT01249664
Clinical Study of Intrastromal Anti-VEGF Injection for Corneal Neovascularization.
NCT07329686
Collateral Damage From the COVID-19 Pandemic Observed in Patients Treated With Intravitreal Injections (IVT) of Anti-angiogenic Agents
NCT04395859
Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection)
NCT01722045
Safety and Efficacy Study of Combretastatin A4 Phosphate to Treat Patients With Choroidal Neovascularization Secondary to Pathologic Myopia
NCT01423149
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Diabetic macular edema
Cases with diabetic macular edema that are prepared for intravitreal injection of anti-vascular endothelial growth factors.
Anti-vascular endothelial growth factors (Anti-VEGFs)
Intravitreal injection of anti-vascular endothelial growth factors (Anti-VEGFs).
Wet age related macular edema
Cases with wet age related macular degenerations that are prepared for intravitreal injection of anti-vascular endothelial growth factors.
Anti-vascular endothelial growth factors (Anti-VEGFs)
Intravitreal injection of anti-vascular endothelial growth factors (Anti-VEGFs).
Retinal vein occlusion
Cases with macular edema secondary to retinal vein occlusion that are prepared for intravitreal injection of anti-vascular endothelial growth factors.
Anti-vascular endothelial growth factors (Anti-VEGFs)
Intravitreal injection of anti-vascular endothelial growth factors (Anti-VEGFs).
Myopic choroidal new vascularization
Cases with myopic choroidal new vascularization that are prepared for intravitreal injection of anti-vascular endothelial growth factors.
Anti-vascular endothelial growth factors (Anti-VEGFs)
Intravitreal injection of anti-vascular endothelial growth factors (Anti-VEGFs).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Anti-vascular endothelial growth factors (Anti-VEGFs)
Intravitreal injection of anti-vascular endothelial growth factors (Anti-VEGFs).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
30 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Benha University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ahmed Abdelshafy
Associate professor of Ophthalmology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ahmed A Tabl
Role: PRINCIPAL_INVESTIGATOR
Benha University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ahmed Abdelshafy Tabl
Banhā, Benha, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Rc-11-2022
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.